… launched its autoimmune disease treatment Avtozma (ingredient: tocilizumab) … the world’s largest pharmaceutical market earlier this month … product, Roche’s Actemra, generated global sales … Celltrion’s other autoimmune drugs -- Zymfentra (infliximab), …

… used earlier in course of treatment. Ciltacabtagene autoleucel (Carvykti; … help them deliver bispecifics—doctors in Wasil’s … (REMS) drug safety program, in which the FDA mandates that … to use prophylactic tocilizumab (Actemra; Genentech) before bispecific …

Pharmaceuticals Drugmaker ties to Osaka University immunology go back to arthritis treatment Actemra Nobel Prize … research partner Chugai Pharmaceutical, as investors hope the Japanese drugmaker';s support …

… drugmakers are paying closer attention to the area. The Boston-based biotech … -6 drugs are already an established category: Roche’s Actemra, an … has not yet disclosed specific trial plans. For now, the … a space where large pharmaceutical groups are once again …

… trial (NCT05592626) at the 2025 European Society for Medical … professor of medicine, head of Early Phase Trials Unit at … action. The most common treatment-related adverse effects (TRAEs) … corticosteroids such as tocilizumab (Actemra),” Italiano said. What Are …

… biosimilar of the autoimmune disease treatment Actemra (active ingredient: tocilizumab), has … (CRS). According to IQVIA, a pharmaceutical market research firm, the Japanese … the local autoimmune disease treatment and anticancer drug markets. Its flagship …

… held by the original drug, including rheumatoid arthritis (RA … global sales of the drug reached 2.6 billion … Actemra biosimilar in Japan, offering patients a more affordable treatment … Japan, a key global pharmaceutical market,” a Celltrion official …

… 5, the FDA approved fremanezumab-vfrm (Ajovy; Teva Pharmaceuticals), to … alignment with its reference drug Actemra. The IL-6 receptor … The treatment was evaluated in the phase 3 ASPEN trial, which … Investigator’s Global Assessment-treatment success (IGA-TS) …

… the ongoing shift toward precision medicine, with accelerated approvals for … the FDA-approved drug spironolactone for the treatment of glioblastoma (GBM). The trial will … biosimilar to tocilizumab (Actemra), to include the treatment of cytokine release …

… its recommendation for vaccination beginning at 6 … alignment with reference tocilizumab (Actemra). Tocilizumab-anoh, an … FDA approved fremanezumab-vfrm (Ajovy; Teva Pharmaceuticals) for the preventive treatment … by phase 3 SPACE trial data, which showed …